Document Detail


Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis.
MedLine Citation:
PMID:  12930374     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Glatiramer acetate (GA) is effective in the treatment of Multiple Sclerosis (MS) presumably by the induction of an immunoregulatory T-cell response. We have previously shown that GA directly induces the Th2 cytokines IL-13 and IL-5 in T-cells in vitro. In the present study we compared the in vitro response to GA in healthy controls, untreated and GA-treated MS patients and tested whether the induction of IL-13 and IL-5 secretion is also detectable in the serum of 25 MS patients treated with GA. Patients were grouped into clinical responders and nonresponders in order to determine a possible correlation with the immunological response. As a result we found a significant increase of IL-13 in the serum of clinical GA-responders whereas IL-13 was not detectable in controls, untreated MS (P < 0.001) and nonresponders (P = 0.015). Similarly, GA-treatment increased serum levels of IL-5 (P = 0.001). The correlation of serum IL-5 and clinical response was also significant (P = 0.039), however, there was an overlap between the different groups. The selective induction of IL-13 and IL-5 but not IL-4 by GA treatment suggests that the specific biological functions of these cytokines might be important for the therapeutic mechanism of GA. Measurement of serum IL-13 and IL-5 levels is a simple and inexpensive tool for monitoring the response to GA in MS patients.
Authors:
E Wiesemann; J Klatt; C Wenzel; F Heidenreich; A Windhagen
Related Documents :
11164954 - Correlation between neutral endopetidase (nep) 3.4.24.11 in serum and the degree of the...
3092994 - Trh and lh-rh distribution in discrete nuclei of the human hypothalamus: evidence for a...
22891254 - Thalamic activation during slightly subphysiological glycemia in humans.
3325334 - Steroids modulate the release of luteinizing hormone from quail pituitary cells.
23382314 - Homocysteine plasma levels in patients treated with antiepileptic drugs depend on folat...
6139274 - Human pancreatic growth hormone-releasing factor stimulates release of growth hormone i...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  133     ISSN:  0009-9104     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-08-21     Completed Date:  2003-10-14     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  454-60     Citation Subset:  IM    
Affiliation:
Department of Neurology, Medical School Hannover, Hannover, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / therapeutic use*
Adult
Analysis of Variance
Disease Progression
Enzyme-Linked Immunosorbent Assay / methods
Female
Humans
Interleukin-13 / blood*
Interleukin-5 / blood*
Lymphocytes / immunology
Male
Middle Aged
Multiple Sclerosis / drug therapy*,  immunology*
Peptides / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Interleukin-13; 0/Interleukin-5; 0/Peptides; 0/copolymer 1
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interf...
Next Document:  T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenecto...